Alimera Sciences Inc (ALIM.O)

ALIM.O on Consolidated Issue listed on NASDAQ Global Market

5.84USD
19 Dec 2014
Price Change (% chg)

$0.11 (+1.92%)
Prev Close
$5.73
Open
$5.72
Day's High
$5.97
Day's Low
$5.65
Volume
1,473,069
Avg. Vol
389,081
52-wk High
$8.44
52-wk Low
$4.29

ALIM.O

Chart for ALIM.O

About

Alimera Sciences, Inc.is a biopharmaceutical company that develops and commercializes prescription ophthalmic pharmaceuticals. The Company advanced product candidate, ILUVIEN, is a tiny, cylindrical polyimide tube that contains 190 g of fluocinolone acetonide (FAc), a corticosteroid with a history of treating ocular diseases.... (more)

Overall

Beta: 1.37
Market Cap (Mil.): $256.92
Shares Outstanding (Mil.): 44.30
Dividend: --
Yield (%): --

Financials

  ALIM.O Industry Sector
P/E (TTM): -- 38.36 38.84
EPS (TTM): -1.13 -- --
ROI: -98.02 18.99 18.26
ROE: -- 19.74 19.12
Search Stocks

Alimera, pSivida eye implant finally wins U.S. approval

- Alimera Sciences Inc and pSivida Corp said the U.S. Food and Drug Administration approved their vision-loss treatment Iluvien, following three rejections.

26 Sep 2014

UPDATE 1-Alimera, pSivida eye implant finally wins U.S. approval

Sept 26 - Alimera Sciences Inc and pSivida Corp said the U.S. Food and Drug Administration approved their vision-loss treatment Iluvien, following three rejections.

26 Sep 2014

Alimera's eye implant Iluvien wins FDA approval

Sept 26 - The Food and Drug Administration has approved Alimera Sciences Inc's and pSivida Corp's vision-loss treatment Iluvien after three rejections.

26 Sep 2014

Competitors

Earnings vs. Estimates

Search Stocks